Systemic treatment of neuroendocrine tumors with hepatic metastases

Turkish Journal of Gastroenterology

Volumn 23, Issue 5, 2012, Pages 427-437

  Demirkan, Binnaz H M ^a   Eriksson, Barbro ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biologic agents; Chemotherapy; Hepatic metastasis; Molecular targeted therapy; Neuroendocrine tumor; Peptide receptor radionuclide therapy

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN; OCTREOTIDE; OXALIPLATIN; PASIREOTIDE; PEGINTERFERON ALPHA2B; PENTETREOTIDE IN 111; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; STEM CELL FACTOR; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGRAPHY; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ECHOGRAPHY; GASTRINOMA; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GLUCAGONOMA; HAZARD RATIO; HUMAN; INSULINOMA; LIVER METASTASIS; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SMALL INTESTINE TUMOR; SYSTEMIC THERAPY; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR SCINTISCANNING; TUMOR VOLUME; VIPOMA; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS;

EID: 84871132726     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2012.0552     Document Type: Review

References (106)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-59. (Pubitemid 36173145)
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and the prognostic factors for neuroendocrine tumors in 35825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.
3. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-64.
4. Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16: 4519-25.
5. Yildiz O, Ozguroglu M, Yanmaz T, et al. Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center. Med Oncol 2010; 27: 1050-6.
6. Demirkan B, Unek IT, Eriksson B, et al. A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report. Turk J Gastroenterol 2009; 20: 214-9.
7. Dogan M, Yalcin B, Ozdemir NY, et al. Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature. Med Oncol 2011 May 27. [Epub ahead of print]
8. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumors of the digestive system. Lyon, France: IARC, 2010; S13-S14.
9. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-62. (Pubitemid 47497934)
10. Klöppel G, Couvelard A, Perren A, et al. Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90: 162-6.
11. Frilling A, Sotiropoulos GC, Li J, et al. Multimodal management of neuroendocrine liver metastases. HPB 2010; 12: 361-79.
12. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17: R53-R73.
13. Oberg K, Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 2000; 482: 329-37. (Pubitemid 32174542)
14. Steinmüller T, Kianmanesh R, Falconi M, et al.; Frascati Consensus Conference participants. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62. (Pubitemid 350308294)
15. Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Curr Opin Oncol 2010; 22: 381-6.
16. O'Toole D, Grossman A, Gross D, et al.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90: 194-202.
17. Oberg K, Eriksson B. Endocrine tumors of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 753-81.
18. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-83.
19. Klöppel G, Couvelard A, Perren A, et al.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90: 162-6.
20. Khasraw M, Gill A, Harrington T, et al. Management of advanced neuroendocrine tumors with hepatic metastasis. J Clin Gastroenterol 2009; 43: 838-47.
21. Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res 2006; 11: 58-65. (Pubitemid 43336943)
22. Rockall AG, Planche K, Power N, et al. Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI. Neuroendocrinology 2009; 89: 288-95.
23. Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DO-TA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5: 42-8. (Pubitemid 36596544)
24. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 2005; 46(Suppl 1): 172S-178S.
25. Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 1431-8.
26. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-18. (Pubitemid 47571404)
27. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-26. (Pubitemid 47476920)
28. Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26: 1489-95.
29. Frilling A, Li J, Malamutmann E, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009; 96: 175-84.
30. Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011; 18: 127-37.
31. Auernhammer CJ, Göke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 2011; 60: 1009-21.
32. Srirajaskanthan R, Toumpanakis C, Meyer T, Caplin ME. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumors. Aliment Pharmacol Ther 2009; 29: 1143-54.
33. Saif MW. Pancreatic neoplasm in 2011: an update. JOP 2011; 12: 316-21.
34. Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72: 517-28.
35. Fendrich V, Michl P, Habbe N, Bartsch DK. Liver-specific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol 2010; 2: 367-73.
36. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation? J Hepatol 2007; 47: 454-75.
37. Kennedy A, Coldwell D, Sangro B, et al. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol 2011 Jan 26. [Epub ahead of print]
38. Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011; 28 (Suppl 1): S286-90.
39. Norton JA. Endocrine tumors of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 2005; 19: 577-83. (Pubitemid 41447719)
40. Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009; (1): CD007118.
41. Eriksson J, Stålberg P, Nilsson A, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008; 32: 930-8.
42. Gomez D, Malik HZ, Al-Mukthar A, et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 2007; 9: 345-51. (Pubitemid 47604634)
43. Landry CS, Scoggins CR, McMasters KM, Martin RC 2nd. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol 2008; 97: 253-8. (Pubitemid 351312166)
44. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 2006; 12: 448-56.
45. Steward MJ, Warbey VS, Malhotra A, et al. Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics 2008; 28: 1131-45.
46. Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72: 517-28.
47. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68: 13-23. (Pubitemid 46589861)
48. Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors, current aspects and new perspectives. J Exp Clin Cancer Res 2010; 29: 19 (1-12).
49. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-73. (Pubitemid 39004355)
50. Plöckinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 145-62.
51. Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009; 90: 184-9.
52. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-6.
53. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17(2): 600-6. (Pubitemid 29075248)
54. Rinke A, Müller HH, Schade-Brittinger C, et al.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63.
55. Ferone D, Saveanu A, Culler MD, et al. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 2007; 156: 23-8.
56. Oberg K, Ferone D, Kaltsas G, et al.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology 2009; 90: 209-13.
57. Plöckinger U, Rindi G, Arnold R, et al.; European Neuroendocrine Tumour Society. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424. (Pubitemid 40874886)
58. Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009; 14: 456-67.
59. Oberg K, Funa K, Alm G. Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. NEJM 1983; 309: 129-33. (Pubitemid 13069520)
60. Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncologica 1991; 30: 519-22.
61. Faiss S, Pape UF, Böhmig M, et al.; International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-96. (Pubitemid 46606312)
62. Eriksson B, Annibale B, Bajetta E, et al.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009; 90: 214-49.
63. Phan AT, Oberg K, Choi J, et al.; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010; 39: 784-98.
64. Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, et al.; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas 2010; 39: 767-74.
65. Boudreaux JP, Klimstra DS, Hassan MM, et al.; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 2010; 39: 753-66.
66. Kaltsas G, Mukherjee JJ, Plowman PN, Grossman AB. The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. Clin Endocrinol (Oxf) 2001; 55: 575-87. (Pubitemid 34204439)
67. Kim S-J, Kim JW, Han S-W, et al. Biologic characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer 2010; 10: 448 (1-11).
68. Madoff D, Gupta S, Ahrar K, et al. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006; 17: 1235-50. (Pubitemid 44259008)
69. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762-71.
70. Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12: 1139-43. (Pubitemid 32834496)
71. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-91. (Pubitemid 46849574)
72. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24: 401-6. (Pubitemid 46630459)
73. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-75.
74. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007; 59: 637-42. (Pubitemid 46295128)
75. Fjällskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-7. (Pubitemid 32861657)
76. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumors with radiolabelled somatostatin analogs. Endocr Relat Cancer 2005; 12: 683-99. (Pubitemid 41815771)
77. van Essen M, Krenning EP, de Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 2007; 46: 723-34. (Pubitemid 47123757)
78. Bushnell DL, O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28: 1652-9.
79. Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G. New treatment strategies in advanced neuroendocrine tumors. Dig Liver Dis 2012; 44: 95-105. Epub 2011 Oct 7.
80. Frilling A, Li J, Malamutmann E, Schmid KW, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. BJS 2009; 96: 175-84.
81. Wang L, Ignat A, Axiotis CA. Differential expression of the PTEN tumor suppresor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 2002; 10: 139-46. (Pubitemid 34553170)
82. Kulke MH. Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr Relat Cancer 2007; 14: 207-19. (Pubitemid 47242623)
83. Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011; 12: 136-48.
84. Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist 2011; 16: 286-95.
85. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
86. Pavel ME, Hainsworth JD, Baudin E, et al.: RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-12.
87. Yao JC, Shah MH, Ito T, et al.; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-23.
88. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-10.
89. van Cutsem E, Seitz JF, Raoul J, et al. Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo. J Clin Oncol 2011; 29 (Suppl 4; Abstr 249).
90. Delbaldo C, Faivre S, Dreyer C, Raymond E. Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential. Ther Adv Med Oncol 2012; 4: 9-18.
91. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Eng J Med 2011; 364: 501-13.
92. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32: 133-8. (Pubitemid 28126179)
93. Fazio N, Cinieri S, Lorizzo K, et al. Biologic targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev 2010; 36S3: S87-S94.
94. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-23.
95. Ruebel K, Leontovich AA, Stilling GA, et al. MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol 2010; 23: 367-75.
96. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66. (Pubitemid 44629897)
97. Garzon R, Fabbri M, Cimmino A, et al. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12: 580-7. (Pubitemid 44780201)
98. Zhang W, Dahlberg JE, Tam W. MicroRNAs in tumorigenesis. Am J Pathol 2007; 171: 728-38.
99. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009; 23: 2152-65.
100. Modlin IM, Moss SF, Chung DC, et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008; 1008: 1282-9.
101. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29: 934-43.
102. ENETS - European Neuroendocrine Tumor Society - http://www.enets.org
103. ESMO - European Society for Medical Oncology - http://www.esmo.org
104. NCCN - National Comprehensive Cancer Network - http://www.nccn.org
105. NANETS - North American NeuroEndocrine Tumor Society - http://www.nanets.net
106. NORDIC Neuroendocrine Tumor Group - http://www.cisionwire.com/nordic- neuroendocrine-tumor-group